NCT02520778 - Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

October 26, 2022

Study Completion Date

December 4, 2023

Conditions

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG

Navitoclax

Given PO

DRUG

Osimertinib

Given PO

Trial Locations (18)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27609

Duke Raleigh Hospital, Raleigh

27710

Duke University Medical Center, Durham

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center, Tampa

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

80045

UCHealth University of Colorado Hospital, Aurora

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

08903

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH